SCTL Stock Overview
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Societal CDMO, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.30 |
| 52 Week High | US$2.19 |
| 52 Week Low | US$0.62 |
| Beta | 0.75 |
| 1 Month Change | -12.75% |
| 3 Month Change | -20.25% |
| 1 Year Change | -16.67% |
| 3 Year Change | -92.65% |
| 5 Year Change | -83.91% |
| Change since IPO | -84.34% |
Recent News & Updates
Shareholder Returns
| SCTL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.7% | -1.6% | 1.7% |
| 1Y | -16.7% | 3.2% | -12.5% |
Return vs Industry: SCTL underperformed the US Pharmaceuticals industry which returned 2.8% over the past year.
Return vs Market: SCTL underperformed the US Market which returned -13.6% over the past year.
Price Volatility
| SCTL volatility | |
|---|---|
| SCTL Average Weekly Movement | 9.6% |
| Pharmaceuticals Industry Average Movement | 11.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SCTL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: SCTL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 258 | J. Enloe | https://www.societalcdmo.com |
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022.
Societal CDMO, Inc. Fundamentals Summary
| SCTL fundamental statistics | |
|---|---|
| Market Cap | US$109.90m |
| Earnings (TTM) | -US$13.07m |
| Revenue (TTM) | US$88.24m |
1.2x
P/S Ratio-8.4x
P/E RatioIs SCTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCTL income statement (TTM) | |
|---|---|
| Revenue | US$88.24m |
| Cost of Revenue | US$65.35m |
| Gross Profit | US$22.89m |
| Other Expenses | US$35.96m |
| Earnings | -US$13.07m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 25.94% |
| Net Profit Margin | -14.81% |
| Debt/Equity Ratio | 281.4% |
How did SCTL perform over the long term?
See historical performance and comparison